Abstract Body

Background: Ritonavir-boosted atazanavir (ATV/r) is a widely used antiretroviral drug though it can cause nephrolithiasis. The aim of this study was to determine the association between polymorphisms in genes encoding proteins that take part in metabolizing process of ATV and drug transporters, and ATV/r-associated nephrolithiasis in HIV-1-infected patients treated with ATV/r. Methodology: The 20 single nucleotide polymorphisms (SNP) in the ABCB1, NR1I2, UGT1A1, SLCO1B1, and CYP3A5 genes were examined in case patients with ATV/r-induced nephrolithiasis (n=31) and controls (n=47). Case patients were those with a clinical diagnosis of nephrolithiasis while on ATV/r, based on new onset of acute flank pain plus one of the following: 1) new-onset hematuria, 2) documented presence of stones by either abdominal ultrasonography or computed tomography, 3) confirmed stone passage. Control patients were consecutively enrolled among those with >2 years of ATV/r experience in whom nephrolithiasis did not occur. Genotyping was performed by allelic discrimination using TaqMan 5’-nuclease assays with standard protocols. Associations between alleles and ATV/r-associated nephrolithiasis were tested by univariate and multivariate logistic regression analyses. Results: None of patient characteristics variables (sex, age, body weight, body mass index, CD4 count, renal function, serum uric acid, co-administration of tenofovir, history of nephrolithiasis and indinavir use) was associated with ATV/r-associated nephrolithiasis. Multivariate analyses adjusted with sex and age showed a significant association between ATV/r-associated nephrolithiasis and three SNPs located in the shared UGT1A1-3’UTR region: any G allele at position 339 (rs1042640, adjusted OR=5.704; 95%CI, 1.592-20.44; p=0.008), any G allele at position 440 (rs8330, adjusted OR=5.704; 95%CI, 1.592-20.44; p=0.008), and any T allele at position *211 (rs10929303, adjusted OR=3.660; 95%CI, 1.163-11.52; p=0.027). The distribution of all other SNPs, including the UGT1A1*28 allele was not different between case and control patients. Conclusions: This is the first study to identify the association between SNPs in UGT1A1 and atazanavir-associated nephrolithiasis. Atazanavir-treated patients with these SNPs might be at higher risk of atazanavir-associated nephrolithiasis than those without.